A multicenter phase II trial of 4′-Iodo-4′-deoxydoxorubicin (IDOX) in primary amyloidosis (AL)

Morie Gertz, Martha Lacy, Angela Dispenzieri, Bruce D. Cheson, Bart Barlogie, Robert A. Kyle, Giovanni Palladini, Susan M. Geyer, Giampaolo Merlini

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Introduction. 4′-Iodo-4′-deoxydoxorubicin (IDOX) has been reported to bind to and lead to the catabolism of amyloid deposits. A multicenter study attempted to develop a dosing schedule to confirm those results. Methods. Patients with biopsy-proven amyloidosis were required to have a cardiac ejection fraction > 50%, ventricular septal thickness < 20 mm, serum creatinine < 2.5 mg per dL, bilirubin ≤ 2.0 mg per dL, neutrophils < 1,500 per μL, and platelets > 100,000 per μL. IDOX was administered intravenously over 1 hour at a dose of 15 mg per m2 once a week for 4 consecutive weeks. This therapy was repeated every 3 months up to 4 times. Results. Twenty-five previously treated and 15 untreated patients with primary amyloidosis (AL) received therapy. Fifteen patients had > 3 g of protein per day in the urine. Eleven patients had an ejection fraction < 60%. One, 2, 3, 4, and 5 organ systems were involved in 22, 10, 4, 3, and 1 patient, respectively. The median time between diagnosis and initiation of IDOX was 17.4 months. There were 6 responses (15%). Twelve of the patients have died. Conclusion. IDOX administered in this protocol was insufficiently active at the current dose.

Original languageEnglish (US)
Pages (from-to)24-30
Number of pages7
JournalAmyloid
Volume9
Issue number1
StatePublished - 2002

Fingerprint

Amyloid Plaques
Amyloidosis
Multicenter Studies
Primary amyloidosis
4'-deoxy-4'-iododoxorubicin
Appointments and Schedules
Urine
Biopsy
Therapeutics
Proteins

Keywords

  • Amyloid
  • Amyloidosis
  • Anthracycline
  • Cardiomyopathy
  • Chemotherapy
  • Nephrotic syndrome

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

A multicenter phase II trial of 4′-Iodo-4′-deoxydoxorubicin (IDOX) in primary amyloidosis (AL). / Gertz, Morie; Lacy, Martha; Dispenzieri, Angela; Cheson, Bruce D.; Barlogie, Bart; Kyle, Robert A.; Palladini, Giovanni; Geyer, Susan M.; Merlini, Giampaolo.

In: Amyloid, Vol. 9, No. 1, 2002, p. 24-30.

Research output: Contribution to journalArticle

Gertz, M, Lacy, M, Dispenzieri, A, Cheson, BD, Barlogie, B, Kyle, RA, Palladini, G, Geyer, SM & Merlini, G 2002, 'A multicenter phase II trial of 4′-Iodo-4′-deoxydoxorubicin (IDOX) in primary amyloidosis (AL)', Amyloid, vol. 9, no. 1, pp. 24-30.
Gertz, Morie ; Lacy, Martha ; Dispenzieri, Angela ; Cheson, Bruce D. ; Barlogie, Bart ; Kyle, Robert A. ; Palladini, Giovanni ; Geyer, Susan M. ; Merlini, Giampaolo. / A multicenter phase II trial of 4′-Iodo-4′-deoxydoxorubicin (IDOX) in primary amyloidosis (AL). In: Amyloid. 2002 ; Vol. 9, No. 1. pp. 24-30.
@article{f17d6338395e4c3996e17629bf9daee1,
title = "A multicenter phase II trial of 4′-Iodo-4′-deoxydoxorubicin (IDOX) in primary amyloidosis (AL)",
abstract = "Introduction. 4′-Iodo-4′-deoxydoxorubicin (IDOX) has been reported to bind to and lead to the catabolism of amyloid deposits. A multicenter study attempted to develop a dosing schedule to confirm those results. Methods. Patients with biopsy-proven amyloidosis were required to have a cardiac ejection fraction > 50{\%}, ventricular septal thickness < 20 mm, serum creatinine < 2.5 mg per dL, bilirubin ≤ 2.0 mg per dL, neutrophils < 1,500 per μL, and platelets > 100,000 per μL. IDOX was administered intravenously over 1 hour at a dose of 15 mg per m2 once a week for 4 consecutive weeks. This therapy was repeated every 3 months up to 4 times. Results. Twenty-five previously treated and 15 untreated patients with primary amyloidosis (AL) received therapy. Fifteen patients had > 3 g of protein per day in the urine. Eleven patients had an ejection fraction < 60{\%}. One, 2, 3, 4, and 5 organ systems were involved in 22, 10, 4, 3, and 1 patient, respectively. The median time between diagnosis and initiation of IDOX was 17.4 months. There were 6 responses (15{\%}). Twelve of the patients have died. Conclusion. IDOX administered in this protocol was insufficiently active at the current dose.",
keywords = "Amyloid, Amyloidosis, Anthracycline, Cardiomyopathy, Chemotherapy, Nephrotic syndrome",
author = "Morie Gertz and Martha Lacy and Angela Dispenzieri and Cheson, {Bruce D.} and Bart Barlogie and Kyle, {Robert A.} and Giovanni Palladini and Geyer, {Susan M.} and Giampaolo Merlini",
year = "2002",
language = "English (US)",
volume = "9",
pages = "24--30",
journal = "Amyloid",
issn = "1350-6129",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - A multicenter phase II trial of 4′-Iodo-4′-deoxydoxorubicin (IDOX) in primary amyloidosis (AL)

AU - Gertz, Morie

AU - Lacy, Martha

AU - Dispenzieri, Angela

AU - Cheson, Bruce D.

AU - Barlogie, Bart

AU - Kyle, Robert A.

AU - Palladini, Giovanni

AU - Geyer, Susan M.

AU - Merlini, Giampaolo

PY - 2002

Y1 - 2002

N2 - Introduction. 4′-Iodo-4′-deoxydoxorubicin (IDOX) has been reported to bind to and lead to the catabolism of amyloid deposits. A multicenter study attempted to develop a dosing schedule to confirm those results. Methods. Patients with biopsy-proven amyloidosis were required to have a cardiac ejection fraction > 50%, ventricular septal thickness < 20 mm, serum creatinine < 2.5 mg per dL, bilirubin ≤ 2.0 mg per dL, neutrophils < 1,500 per μL, and platelets > 100,000 per μL. IDOX was administered intravenously over 1 hour at a dose of 15 mg per m2 once a week for 4 consecutive weeks. This therapy was repeated every 3 months up to 4 times. Results. Twenty-five previously treated and 15 untreated patients with primary amyloidosis (AL) received therapy. Fifteen patients had > 3 g of protein per day in the urine. Eleven patients had an ejection fraction < 60%. One, 2, 3, 4, and 5 organ systems were involved in 22, 10, 4, 3, and 1 patient, respectively. The median time between diagnosis and initiation of IDOX was 17.4 months. There were 6 responses (15%). Twelve of the patients have died. Conclusion. IDOX administered in this protocol was insufficiently active at the current dose.

AB - Introduction. 4′-Iodo-4′-deoxydoxorubicin (IDOX) has been reported to bind to and lead to the catabolism of amyloid deposits. A multicenter study attempted to develop a dosing schedule to confirm those results. Methods. Patients with biopsy-proven amyloidosis were required to have a cardiac ejection fraction > 50%, ventricular septal thickness < 20 mm, serum creatinine < 2.5 mg per dL, bilirubin ≤ 2.0 mg per dL, neutrophils < 1,500 per μL, and platelets > 100,000 per μL. IDOX was administered intravenously over 1 hour at a dose of 15 mg per m2 once a week for 4 consecutive weeks. This therapy was repeated every 3 months up to 4 times. Results. Twenty-five previously treated and 15 untreated patients with primary amyloidosis (AL) received therapy. Fifteen patients had > 3 g of protein per day in the urine. Eleven patients had an ejection fraction < 60%. One, 2, 3, 4, and 5 organ systems were involved in 22, 10, 4, 3, and 1 patient, respectively. The median time between diagnosis and initiation of IDOX was 17.4 months. There were 6 responses (15%). Twelve of the patients have died. Conclusion. IDOX administered in this protocol was insufficiently active at the current dose.

KW - Amyloid

KW - Amyloidosis

KW - Anthracycline

KW - Cardiomyopathy

KW - Chemotherapy

KW - Nephrotic syndrome

UR - http://www.scopus.com/inward/record.url?scp=0036130774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036130774&partnerID=8YFLogxK

M3 - Article

C2 - 12000194

AN - SCOPUS:0036130774

VL - 9

SP - 24

EP - 30

JO - Amyloid

JF - Amyloid

SN - 1350-6129

IS - 1

ER -